Cell therapy developers are under pressure to accelerate safety testing without compromising quality or regulatory compliance. Download today to learn how PCR-based mycoplasma and sterility testing can replace slow culture methods, delivering faster, more flexible, and more reliable results.

As biopharma manufacturers scale biologics to commercial production, choosing the right bioreactor size can determine long-term efficiency and cost. Download this free white paper to learn why 5,000L single-use bioreactors represent the commercial sweet spot for complex biologics—balancing flexibility, capacity, and economics.

Early-stage biologics don’t have time for trial-and-error. Download the free white paper to learn how a technology-driven approach—combining AI/ML, advanced cell line development, and intensified processes—can help you reach IND and first-in-human milestones faster.

Take this quick survey to help shape the State of Patient Access Technology 2026 and benchmark how pharma patient access programs use technology today—what’s working, what’s slowing teams down, and what tools are emerging. Share your perspective now by completing the survey.

A short industry brief on how CGT manufacturers can replace paper-based processes with scalable digital workflows—improving chain-of-identity tracking, accelerating batch release, and reducing delays that can impact patient treatment windows. Download the brief to see the roadmap.

Download this free infographic to see how life sciences teams can use privacy-first, HIPAA-compliant real-world data to build precise HCP and patient audiences, optimize campaigns in flight, and measure real outcomes—not just clicks.

Modern healthcare innovation goes beyond connecting systems—it requires an ecosystem approach that enables proactive, coordinated, and patient-focused engagement. This whitepaper explores how data, AI, and collaboration transform care delivery and outcomes. Download the free whitepaper to learn more.